Mirati Therapeutics, Inc. (MRTX): Business Model Canvas

Key Partnerships

- Collaborations with pharma and biotech companies: Mirati Therapeutics, Inc. establishes strategic partnerships with pharmaceutical and biotechnology companies to leverage their expertise, resources, and networks to accelerate the development and commercialization of its novel therapeutics. These collaborations help MRTX gain access to additional funding, research capabilities, and distribution channels. - Academic and research institutions: Mirati Therapeutics, Inc. collaborates with academic and research institutions to access cutting-edge scientific knowledge, expertise, and technology. These partnerships enable MRTX to conduct preclinical and clinical studies, validate its drug candidates, and broaden its intellectual property portfolio. - Medical technology providers: MRTX partners with medical technology providers to leverage their innovative tools, platforms, and systems for drug discovery, development, and patient monitoring. These collaborations enhance the efficiency, accuracy, and cost-effectiveness of Mirati's research and development efforts. - Clinical trial networks: Mirati Therapeutics, Inc. collaborates with clinical trial networks to facilitate the recruitment, enrollment, and management of patients in its clinical studies. These partnerships help MRTX conduct large-scale trials across multiple sites, countries, and regulatory jurisdictions, accelerating the regulatory approval and commercialization of its therapies. Overall, Mirati Therapeutics, Inc. forms key partnerships with a diverse range of stakeholders to drive innovation, collaboration, and growth in the biopharmaceutical industry. These strategic alliances enable MRTX to advance its pipeline, expand its market reach, and achieve its mission of developing breakthrough treatments for cancer patients.

Key Activities

Mirati Therapeutics, Inc. engages in several key activities to drive its business model forward:

• Research and development of targeted cancer therapies: Mirati Therapeutics focuses on developing innovative therapies for various types of cancer. This involves conducting extensive research to identify potential drug targets and developing novel compounds to target these specific mutations.
• Clinical trials and drug testing: Once a potential drug candidate is identified, Mirati Therapeutics conducts rigorous clinical trials to evaluate its safety and efficacy. These trials are essential for obtaining regulatory approval and bringing new therapies to market.
• Regulatory compliance and quality assurance: Mirati Therapeutics places a strong emphasis on regulatory compliance and quality assurance to ensure that its therapies meet the highest standards of safety and efficacy. This involves working closely with regulatory agencies such as the FDA to navigate the complex drug approval process.
• Marketing and advocacy: In order to bring its therapies to market successfully, Mirati Therapeutics engages in marketing and advocacy efforts to raise awareness about its products and educate healthcare providers and patients about the benefits of its targeted cancer therapies.

By focusing on these key activities, Mirati Therapeutics is able to advance its mission of developing life-changing therapies for cancer patients and improve outcomes in the fight against this devastating disease.

Key Resources

Mirati Therapeutics, Inc. (MRTX) relies on several key resources to operate and drive its business forward. These resources are critical for the company's success in developing innovative cancer treatments.

• Intellectual Property: Mirati Therapeutics holds a strong portfolio of intellectual property, including patents protecting its novel drug candidates and technologies. This intellectual property gives the company a competitive advantage and ensures exclusivity in the market.
• Scientific and Medical Expertise: Mirati Therapeutics boasts a team of highly skilled scientists, researchers, and medical professionals who possess expertise in oncology, pharmacology, and molecular biology. This expertise is essential for developing cutting-edge therapies and advancing the company's pipeline.
• Advanced Biotechnological Facilities: The company has access to state-of-the-art biotechnological facilities that are equipped with the latest instruments and technologies for drug discovery, development, and manufacturing. These facilities play a crucial role in bringing innovative therapies from the lab to the clinic.
• Funding and Investments: Mirati Therapeutics has secured funding from investors and strategic partners to support its research and development efforts. This financial backing enables the company to conduct clinical trials, expand its pipeline, and move closer to commercialization of its drug candidates.

Value Propositions

Mirati Therapeutics, Inc. focuses on providing innovative targeted therapies for specific cancer types, offering a unique value proposition to patients, healthcare providers, and investors. By developing precision medicine solutions, Mirati aims to improve the efficacy and safety profile of cancer treatments, leading to better outcomes for patients.

• Innovative targeted therapies: Mirati's focus on developing targeted therapies for specific cancer types sets them apart from traditional broad-spectrum treatments. By targeting specific genetic mutations or biomarkers, Mirati's therapies have the potential to be more effective and less toxic than traditional treatments.
• Increased efficacy and safety profile: Through rigorous research and development, Mirati strives to improve the efficacy and safety profile of their treatments. By targeting the underlying mechanisms of cancer, Mirati's therapies have the potential to deliver better outcomes with fewer side effects.
• Ongoing development of novel therapeutics: Mirati is dedicated to advancing the field of oncology by continuously developing novel therapeutics. By staying at the forefront of scientific innovation, Mirati can address unmet medical needs and improve patient outcomes.
• Commitment to personalized medicine: Mirati's commitment to personalized medicine means that each patient receives a treatment plan tailored to their specific genetic profile. By understanding the unique characteristics of each patient's cancer, Mirati can optimize treatment outcomes and minimize unnecessary side effects.

Customer Segments

Mirati Therapeutics serves a diverse range of customer segments within the healthcare industry, including patients, healthcare providers, pharmaceutical companies, and investors. Each segment has distinct needs and expectations that Mirati aims to address through its innovative therapies and personalized approach to cancer treatment.

• Patients: Patients with specific cancer types who are seeking targeted therapies with improved efficacy and safety profiles.
• Healthcare providers: Oncologists, nurses, and other healthcare professionals who are looking for advanced treatment options that can improve patient outcomes.
• Pharmaceutical companies: Partners and collaborators who are interested in licensing or co-developing Mirati's novel therapeutics to expand their oncology pipeline.
• Investors: Venture capitalists, institutional investors, and stakeholders who are looking to invest in a biopharmaceutical company with a strong track record of scientific innovation and commercial success.

Customer Relationships

Building trust through transparent communication:

We believe in establishing trust with our customers through clear and honest communication. This includes providing accurate information about our products, services, and clinical trials to patients, healthcare professionals, and the wider community. By being transparent, we aim to build strong relationships based on trust and credibility.

Patient support programs:

At Mirati Therapeutics, we are committed to providing comprehensive support programs for patients who are using our therapies. These programs offer resources, educational materials, and assistance with navigating insurance coverage and financial assistance options. By prioritizing the needs of our patients, we aim to improve their overall treatment experience and outcomes.

Engaging with healthcare professionals:

• Our team actively engages with healthcare professionals to discuss the benefits of our therapies and explore opportunities for collaboration.
• We provide healthcare professionals with up-to-date information on our products and clinical trials to support their decision-making process.
• We also offer training and educational resources to help healthcare professionals effectively prescribe and administer our therapies.

Community and patient advocacy:

• We are dedicated to engaging with patient advocacy groups and community organizations to raise awareness about the diseases we are targeting and the impact of our therapies.
• By listening to patients and their advocates, we gain valuable insights that help us improve our products and services to better meet their needs.
• We actively participate in community events, conferences, and educational programs to support patients and further research in relevant therapeutic areas.

Channels

As part of Mirati Therapeutics, Inc.'s business model canvas, the company utilizes various channels to reach its target audience and distribute its innovative therapies. These channels include:

• Direct sales to healthcare providers: Mirati Therapeutics, Inc. has a dedicated sales team that directly reaches out to healthcare providers, including physicians, hospitals, and treatment centers. This direct approach allows the company to build relationships with key decision-makers and provide them with information about the benefits of Mirati's therapies.
• Online platforms for information and engagement: Mirati Therapeutics, Inc. leverages online platforms, including its website and social media channels, to provide information about its products, ongoing clinical trials, and research developments. These platforms also serve as a way to engage with patients, caregivers, and healthcare professionals, fostering a sense of community and support.
• Conferences and scientific forums: Mirati Therapeutics, Inc. participates in various conferences, symposiums, and scientific forums to showcase its research and findings, as well as to network with other industry professionals. These events provide a platform for the company to highlight its expertise and innovation in the field of oncology.
• Partnerships with medical distributors: Mirati Therapeutics, Inc. has established partnerships with medical distributors to ensure the efficient distribution of its products to healthcare facilities and providers. These partnerships help the company reach a wider audience and ensure that its therapies are readily available to those who need them.

Customer Segments

Cancer patients and their families:

Mirati Therapeutics, Inc. primarily focuses on developing innovative precision oncology treatments for cancer patients. The company's customer segment includes cancer patients seeking targeted therapies that can provide more effective treatment options with less toxicity compared to traditional chemotherapy. Mirati's products aim to improve patient outcomes and quality of life, which is a significant value proposition for this customer segment. The company engages with patients and their families to understand their needs and collectively work towards advancements in cancer care.

Oncologists and healthcare professionals:

Another key customer segment for Mirati Therapeutics, Inc. includes oncologists and healthcare professionals who are involved in the diagnosis, treatment, and management of cancer patients. These professionals rely on cutting-edge research and innovative therapies to provide the best possible care to their patients. By targeting this customer segment, Mirati positions itself as a trusted partner in the oncology community, providing access to new treatment options and contributing to the advancement of precision medicine in cancer care.

Hospitals and cancer treatment centers:

Mirati Therapeutics, Inc. collaborates with hospitals and cancer treatment centers to ensure that its precision oncology therapies are accessible to patients in need. These institutions play a crucial role in delivering cancer care and are essential partners for the company in reaching a broader patient population. By working closely with hospitals and cancer treatment centers, Mirati ensures that its products are integrated into clinical practice and have a meaningful impact on cancer treatment outcomes.

Research institutions and academia:

Research institutions and academia are important customer segments for Mirati Therapeutics, Inc. as they contribute to the scientific advancement of precision oncology. The company collaborates with leading researchers and academic institutions to conduct clinical trials, investigate novel biomarkers, and identify potential new drug targets. By engaging with this customer segment, Mirati expands its scientific expertise, accesses cutting-edge research capabilities, and drives innovation in the field of precision medicine for cancer.

Cost Structure

Mirati Therapeutics, Inc. operates with a strong focus on research and development to drive innovation in the field of oncology. As a result, a significant portion of the company's costs is allocated to research and development expenses. This includes investment in cutting-edge technologies, collaboration with academic institutions, and conducting clinical trials to bring new therapies to the market.

• Research and Development Expenses: Mirati Therapeutics invests heavily in research and development activities to discover and develop novel cancer therapies. These expenses include costs related to preclinical studies, clinical trials, and drug discovery efforts.
• Manufacturing and Operational Costs: Once a drug candidate progresses through clinical trials and receives regulatory approval, the company incurs costs related to manufacturing the product at scale. This includes expenses for raw materials, manufacturing facilities, and quality control measures to ensure product consistency.
• Marketing and Sales Expenditures: Mirati Therapeutics allocates resources to market and promote its approved therapies to healthcare providers, payers, and patients. This includes expenses for advertising, sales force salaries, and distribution channels to maximize product adoption and revenue generation.
• Regulatory and Compliance Costs: As a biopharmaceutical company, Mirati Therapeutics must comply with strict regulatory requirements imposed by health authorities such as the FDA. Ensuring compliance with regulations and maintaining quality standards incurs additional costs for the company.

Revenue Streams

Mirati Therapeutics, Inc. generates revenue through various streams that support the growth and sustainability of the business. These revenue streams include:

• Sales of approved pharmaceutical products: One of the primary revenue streams for Mirati Therapeutics is the sales of its approved pharmaceutical products. These products are developed through extensive research and clinical trials to address unmet medical needs in oncology.
• Licensing agreements and royalties: Mirati Therapeutics enters into licensing agreements with other pharmaceutical companies to leverage its technology, intellectual property, and expertise. In return, Mirati receives royalties on product sales, providing a steady stream of revenue.
• Research funding and grants: Mirati Therapeutics secures research funding and grants from government agencies, foundations, and other organizations to support its ongoing research and development efforts. This funding helps advance the pipeline of innovative therapies.
• Collaborations and partnerships: Mirati Therapeutics collaborates with academic institutions, research organizations, and other biopharmaceutical companies to combine expertise and resources. These collaborations result in shared revenue from joint projects and partnerships.